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1. Introduction
Every emergency physician has seen diabetic foot ulcers in their nascent stage, at a stage
requiring minimal treatment with good follow-up, when they require aggressive treatment,
and at a stage when amputation is a foregone conclusion. Ulcerations of the foot in diabetics
are common; most diabetics will get them. Not only are they disabling, they also are limb- and
life-threatening. [1]
It is estimated that approximately 15% of diabetic people world-wide will at some stage
develop diabetic foot ulceration. The prevalence of active foot ulceration varies from approx‐
imately 1% in certain European and North American studies to more than 11% in reports from
some African countries (table 1). Although there have been many developments in recent years
which encourage optimism for future improvement in diabetic foot care, there is still much to
be done; the recent data from the Netherlands show that with a concerted team approach, it
is possible to increase the numbers of foot clinics with the provision of podiatry services by
more than 100%. However, many countries still lack proper podiatry and specialist nursing
provision and there remains much to be done in the next millennium to improve the lot of the
diabetic patient with foot problems. [2,3] In general, in diabetic patients, the incidence of foot
ulcers ranges from 1.0% to 4.1%, and the incidence of lower-extremity amputations ranges
from 2.1 to 13.7 per 1000. [4-6]
The nerves of the leg and foot serve to propel the body through the actions of the legs, feet,
and toes while maintaining balance, both while the body is moving and when it is at rest.
Sensory nerves are of course present throughout the lower extremities; however, with the
exception of the bottom of the foot, they play a lesser role here than in the upper extremities.
Primarily, this section of the peripheral nervous system sends and receives signals regarding
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Study (country) Population base N Prevalence(%)
Annual
incidencea(%
)
Ulcer
definition
Ulcer ascertainment
method
Rith-Najarian et
al. (US)
Chippewa Indian
residents with
diabetes
266 -
0.6 (Non-
neuropathic
subjects)
Full thickness
plantar foot
lesion
Retrospective review of
medical records/clinical
examinations
Walters et al. (UK)
Registered patients
with diabetes from
10 UK general
practices
1077
2.9 (current)
7.4 (History of
ulcer)
- Wagner grade≥1 foot lesion
Direct examination and
structured interview
Moss et al. (US)
Population-based
samples of persons
with diabetes
1834
10.6 (History
of ulcers at
baseline)
2.2 ???
Medical history
questionnaire
administered at baseline
and 4 years later
Kumar et al. (UK)
Type 2 diabetes
patients registered in
three UK cities
811
1.4 (Current)
5.3 (History of
ulcer)
- Wagner grade≥1 foot lesion
Direct exam by trained
observers (current), and
structured interview
(history of ulcer)
Abbott et al. (UK)
Randomized
controlled trial
cohort
1035 - 3.6
Full-thickness
lesion
requiring
hospital
treatment
Direct examination at
least every 13 weeks
Ramsey et al. (US)
Registered adult type
1 or 2 diabetes
patients in a large
HMO (1992-1995)
8905 - 1.9
ICD-codes:
707.1 (ulcer of
lower leg)
Medical billing record
audit
Abbott et al. (UK)
Registered type 1 and
2 diabetes patients in
six UK districts
9710 1.7 (Current) 2.2 Wagner grade≥1 foot lesion
Clinical examination (plus
chart review)
Muller et al.
(Netherland)
1993-1998 registered
type 2 diabetes
patients
3827
person-
years
- 2.1
Full-thickness
skin loss on the
foot
Abstracted medical
records
Centers for
Disease Control
and Prevention
(US)
US BRFSS
respondents with
diabetes, 2000-2002b
NS 11.8 (Historyof ulcer) -
Foot sore that
did not heal
for >4 weeks
Random-digit-dialed
telephone interview
???, not specified.
a Incidence is annualized unless otherwise noted.
b BRFSS, Behavioral Risk Factor Surveillance Survey.
Table 1. Selected population-based studies estimating incidence and prevalence of diabetic foot ulcers (adapted from
LeMaster and Reiber, 2006) [7]
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locomotion of the body. Some of the impulses are sent from various parts of the brain and
spinal cord; some come from sense organs located in the joints, ligaments, and tendons; and
some come from the muscles themselves.
Figure 1. Nerves of foot. (adapted from Encyclopedia Britanica 2007)
The nerves of the leg and foot include the sacral plexus, lumbar plexus, femoral nerve, sciatic
nerve, common fibular nerve, superficial fibular nerve, saphenous nerve, sural nerve, the deep
and superficial peroneal nerves, and the tibial nerve (figure 1).
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The nerves deliver messages to the brain that bring information about the angles and position
of joints, the length and tension of muscles, or even the speed of movements so that through
the interaction of the nervous system with the muscles of the lower extremities, balance may
be maintained. The average nerve running from the base of the spine to the tip of a toe is about
three feet long. This includes a major neural transmission network within the legs that
produces contractions of groups of muscles and is responsible for larger muscular functions,
such as running, walking or swimming. Finer nerve bundles command the many small bones
of the toes to create the constant, subtle shifting of the feet that keeps us from falling down.
2. Peripheral neuropathy
Peripheral neuropathy is damage to nerves of the peripheral nervous system, which may be
caused either by diseases of or trauma to the nerve or the side-effects of systemic illness.
The four cardinal patterns of peripheral neuropathy are polyneuropathy, mononeuropathy,
mononeuritis multiplex and autonomic neuropathy. The most common form is (symmetrical)
peripheral polyneuropathy, which mainly affects the feet and legs. The form of neuropathy
may be further broken down by cause, or the size of predominant fiber involvement, i.e., large
fiber or small fiber peripheral neuropathy. Frequently the cause of a neuropathy cannot be
identified and it is designated as being idiopathic.
Neuropathy may be associated with varying combinations of weakness, autonomic changes,
and sensory changes. Loss of muscle bulk or fasciculations, a particular fine twitching of
muscle, may be seen. Sensory symptoms encompass loss of sensation and "positive" phenom‐
ena including pain. Symptoms depend on the type of nerves affected (motor, sensory, or
autonomic) and where the nerves are located in the body. One or more types of nerves may
be affected. Common symptoms associated with damage to the motor nerve are muscle
weakness, cramps, and spasms. Loss of balance and coordination may also occur. Damage to
the sensory nerve can produce tingling, numbness, and a burning pain. Pain associated with
this nerve is described in various ways such as the following: burning, freezing, or electric-
like, extreme sensitivity to touch. The autonomic nerve damage causes problems with
involuntary functions leading to symptoms such as abnormal blood pressure and heart rate,
reduced ability to perspire, constipation, bladder dysfunction (e.g., incontinence), and sexual
dysfunction. [8-10]
3. Sensory neuropathy
Sensory neuropathy affects the nerves that carry messages from the skin, bones and muscles
to the brain. As the name suggests, it tends to influence the senses, in particular touch, and
affects how we feel temperature, pain and other sensations. It is the most common form of
neuropathy, mainly occurring in nerves in the feet and legs, but can sometimes occur in the
arms and hands. It can lead to a loss of feeling and a failure to sense pain. For example, if you
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trod on something sharp, stepped in to a hot bath or wore ill-fitting shoes, you may not be
aware of damage to your feet. This lack of sensation can lead to damage becoming worse, and
the potential for infection. Neuropathic ulcers may also occur. [11]
The symptoms of sensory neuropathy can include pain and numbness, tingling in the hands,
legs or feet and extreme sensitivity to touch. Some treatments are available to help with the
pain and tablets that are usually used for depression but can also have a calming effect on the
nerves.
A test should be carried out at least every year, to check for signs of this type of neuropathy.
4. Motor neuropathy
Motor neuropathy affects the nerves that transmit signals to the muscles enabling them to carry
out movements like walking and moving the hands. Sometimes painful, it causes muscle
weakness and, in areas like the thigh, muscle wasting can occur. However it is possible for
some people to recover from this condition after a period of time.
If the nerves that supply the small muscles in your feet are affected, motor neuropathy can
lead to the development of foot deformities and alteration in the pressure distribution with
walking or activity. Wasting of these muscles may ultimately cause collapse of the arch and
loss of stability, which results in forming the 'rocker bottom' or Charcot’s foot, where a loss of
sensation and weakened muscles cause bones in the foot to fracture or break when stressed.
As you may not feel the damage, subsequently you may not heal properly and this can result
in the shape of the foot becoming distorted. Your podiatrist will know more about treatments
for this. [12]
5. Autonomic neuropathy
The final type of nerve problem is an “autonomic neuropathy.” In this type of neuropathy, the
nerves that control sweating are damaged. Dry skin occurs as a result of damage to these
nerves. Sweating is important for heat reduction but it is also important for skin moisture
balance. Without sweat, the skin dries out and cracks. This can be dangerous because germs
can enter through the cracks and cause infection. Dry and cracked skin should be treated with
prescription moisturizing creams and regular professional foot care. Autonomic neuropathy
is a form of polyneuropathy which affects the non-voluntary, non-sensory nervous system
(i.e., the autonomic nervous system) affecting mostly the internal organs such as the bladder
muscles, the cardiovascular system, the digestive tract, and the genital organs. These nerves
are not under a person's conscious control and function automatically. Autonomic nerve fibers
form large collections in the thorax, abdomen and pelvis outside spinal cord, however they
have connections with the spinal cord and ultimately the brain. Most commonly autonomic
neuropathy is seen in persons with long-standing diabetes mellitus type 1 and 2. In most but
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not all cases, autonomic neuropathy occurs alongside other forms of neuropathy, such as
sensory neuropathy.
Autonomic neuropathy is one cause of malfunction of the autonomic nervous system, but not
the only one; some conditions affecting the brain or spinal cord can also cause autonomic
dysfunction, such as multiple system atrophy, and therefore cause similar symptoms to
autonomic neuropathy.
The signs and symptoms of autonomic neuropathy include the following:
• Urinary bladder conditions: bladder incontinence or urine retention
• Gastrointestinal tract: dysphagia, abdominal pain, nausea, vomiting, malabsorption, fecal
incontinence, gastroparesis, diarrhea, constipation
• Cardiovascular system: disturbances of heart rate (tachycardia, bradycardia), orthostatic
hypotension, inadequate increase of heart rate on exertion
• Other areas: hypoglycemia unawareness, genital impotence, sweat disturbances. [9]
6. Diabetic neuropathy
Most diabetics experience some type of neuropathy, a leading predisposing factor to devel‐
opment of ulcers. More than 60% of diabetic foot ulcers are the result of underlying neuropathy.
[11,13] Diabetics have altered peripheral sensation of the foot, with loss of the protective
sensation that renders the individual unaware of the beginning of an ulcer or the actual
ulceration process. Diabetic neuropathy also alters the microcirculation of the foot, resulting
in a reduced distribution of blood to the areas of need. Nerve damage in diabetic neuropathy
occurs when blood sugar is poorly controlled for prolonged periods of time. Involvement of
these nerves results in loss of the normal protective sensation that we rely upon to avoid injury.
Loss of the normal pain threshold may result in prolonged and repetitive trauma to the foot.
Overcompensation by other muscles can lead to other foot deformities including 'hammer' or
'claw' toes. These abnormalities lead to pressure points that are then at great risk for ulceration.
Even the dry, brittle skin caused by diminished sweating is due to neuropathy affecting
specialized nerves within the skin. This makes the skin prone to cracking and fissuring, thus
allowing entry of bacteria even in the absence of a large sore. Subsequent infection and abscess
formation may damage far more tissue than is apparent from the overlying ulcer.
The development of neuropathy in affected patients has been shown in animal and in vitro
models to be a result of hyperglycemia-induced metabolic abnormalities. One of the more
commonly described mechanisms of action is the polyol pathway. In the development of
neuropathy, the hyperglycemic state leads to an increase in action of the enzymes aldose
reductase and sorbitol dehydrogenase. This results in the conversion of intracellular glucose
to sorbitol and fructose. The accumulation of these sugar products results in a decrease in the
synthesis of nerve cell myoinositol, required for normal neuron conduction. Additionally, the
chemical conversion of glucose results in a depletion of nicotinamide adenine dinucleotide
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phosphate stores, which are necessary for the detoxification of reactive oxygen species and for
the synthesis of the vasodilator nitric oxide. There is a resultant increase in oxidative stress on
the nerve cell and an increase in vasoconstriction leading to ischemia, which will promote
nerve cell injury and death. Hyperglycemia and oxidative stress also contribute to the
abnormal glycation of nerve cell proteins and the inappropriate activation of protein kinase
C, resulting in further nerve dysfunction and ischemia.
Neuropathy in diabetic patients is manifested in the motor, autonomic, and sensory compo‐
nents of the nervous system. [14] Damage to the innervations of the intrinsic foot muscles leads
to an imbalance between flexion and extension of the affected foot. This produces anatomic
foot deformities that create abnormal bony prominences and pressure points, which gradually
cause skin breakdown and ulceration.
As trauma occurs at the affected site, patients are often unable to detect the insult to their lower
extremities. As a result, many wounds go unnoticed and progressively worsen as the affected
area is continuously subjected to repetitive pressure and shear forces from ambulation and
weight bearing. [15-20]
7. Vascular disease
Peripheral arterial disease is a contributing factor to the development of foot ulcers in up to
50% of cases. [21] It commonly affects the tibial and peroneal arteries of the calf. Endothelial
cell dysfunction and smooth cell abnormalities develop in peripheral arteries as a consequence
of the persistent hyperglycemic state. [22] There is a resultant decrease in endothelium-derived
vasodilators leading to constriction. Further, the hyperglycemia in diabetes is associated with
an increase in thromboxane A2, a vasoconstrictor and platelet aggregation agonist, which leads
to an increased risk for plasma hypercoagulability. [23] There is also the potential for altera‐
tions in the vascular extracellular matrix leading to stenosis of the arterial lumen. [23] More‐
over, smoking, hypertension, and hyperlipidemia are other factors that are common in diabetic
patients and contribute to the development of peripheral arterial disease. [14] Cumulatively,
this leads to occlusive arterial disease that results in ischemia in the lower extremity and an
increased risk of ulceration in diabetic patients.
8. The extracellular matrix, fibroblast and keratinocyte
The extracellular matrix (ECM) is the non-cellular component present within all tissues and
organs, and not only does provides essential physical scaffolding for the cellular constituents
but also initiates crucial biochemical and biomechanical cues that are required for tissue
morphogenesis, differentiation and homeostasis. The importance of the ECM is vividly
illustrated by the wide range of syndromes, which can be anything from minor to severe, that
arise from genetic abnormalities in ECM proteins. Although, fundamentally, the ECM is
composed of water, proteins and polysaccharides, each tissue has an ECM with a unique
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composition and topology that is generated during tissue development through a dynamic
and reciprocal, biochemical and biophysical dialogue between the various cellular components
(e.g. epithelial, fibroblast, adipocyte, endothelial elements) and the evolving cellular and
protein microenvironment. Indeed, the physical, topological, and biochemical composition of
the ECM is not only tissue-specific, but is also markedly heterogeneous. Cell adhesion to the
ECM is mediated by ECM receptors, such as integrins, discoidin domain receptors and
syndecans. Adhesion mediates cytoskeletal coupling to the ECM and is involved in cell
migration through the ECM. Moreover, the ECM is a highly dynamic structure that is con‐
stantly being remodeled, either enzymatically or non-enzymatically, and its molecular
components are subjected to a myriad of post-translational modifications. Through these
physical and biochemical characteristics the ECM generates the biochemical and mechanical
properties of each organ, such as its tensile and compressive strength and elasticity, and also
mediates protection by a buffering action that maintains extracellular homeostasis and water
retention. In addition, the ECM directs essential morphological organization and physiological
function by binding growth factors (GFs) and interacting with cell-surface receptors to elicit
signal transduction and regulate gene transcription.
A fibroblast is a type of cell that synthesizes the extracellular matrix and collagen, the structural
framework (stroma) for animal tissues, and plays a critical role in wound healing. Fibroblasts
are the most common cells of connective tissue in animals. Inactive fibroblasts, which are also
called fibrocytes, are smaller and spindle shaped. Although disjointed and scattered when they
have to cover a large space, fibroblasts when crowded often locally align in parallel clusters.
Fibroblasts make collagens, glycosaminoglycans, reticular and elastic fibers, glycoproteins
found in the extracellular matrix and cytokine TSLP. Growing individuals' fibroblasts are
dividing and synthesizing ground substance. Tissue damage stimulates fibrocytes and induces
the mitosis of fibroblasts. Unlike the epithelial cells lining the body structures, fibroblasts do
not form flat monolayers and are not restricted by a polarizing attachment to a basal lamina
on one side, although they may contribute to basal lamina components in some situations
Fibroblasts can also migrate slowly over substratum as individual cells, again in contrast to
epithelial cells. While epithelial cells form the lining of body structures, it is fibroblasts and
related connective tissues which sculpt the "bulk" of an organism.
Keratinocyte is the predominant cell type in the epidermis, the outermost layer of the skin,
constituting 95% of the cells found there. Those keratinocytes found in the basal layer (Stratum
germinativum) of the skin are sometimes referred to as "basal cells" or "basal keratinocytes.
Wounds to the skin will be repaired in part by the migration of keratinocytes to fill in the
gap created by the wound. The first set of keratinocytes to participate in that repair come
from the  bulge  region  of  the  hair  follicle  and  will  only  survive  transiently.  Within  the
healed epidermis they will  be replaced by keratinocytes originating from the epidermis.
At the opposite, epidermal keratinocytes, can contribute to de novo hair follicle formation
during the healing of large wounds. Keratinocytes migrate with a rolling motion during
the process of wound healing.
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9. Extracellular matrix, fibroblast and keratinocyte in diabetic foot ulcer
Diabetic nephropathy (DN) is a serious complication in diabetes and is characterized by
excessive deposition of extracellular matrix proteins in the mesangium and basement mem‐
brane. Major typical morphological changes are the result of changes in the extracellular matrix
(ECM). One important ECM component, the proteoglycans (PGs), shows a more complex
pattern of changes in DN. PGs in basement membranes are decreased. The amounts and
structures of heparan sulfate chains are changed, and such changes affect levels of growth
factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endo‐
thelial cells. Enzymes modulating heparan sulfate structures, such as heparanase and sulfa‐
tases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such
as matrix metalloproteinases and serine proteases, such as plasminogen activator, as well as
their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in
plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hypergly‐
cemia per se affect ECM synthesis and turnover in DN. Therefore, ECM components are being
evaluated to be used as markers for DN. [24-27]
10. Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a family of nine or more highly homologous Zn(++)-
endopeptidases that collectively cleave most if not all of the constituents of the extracellular
matrix.
In diabetic foot ulcers there is an excess of MMPs and a decrease of the tissue inhibitors of
MMPs (TIMPs). This imbalance is probably one cause of impaired healing. However, little is
known about changes in MMPs during wound healing. A high level of MMP-1 seems essential
to wound healing, while an excess of MMP-8 and -9 is deleterious, and could be a target for
new topical treatments. The MMP-1/TIMP-1 ratio is a predictor of wound healing in diabetic
foot ulcers. [28]
11. Risk factors in diabetic foot
Early recognition and management of risk factors is important for reducing morbidity of foot
ulceration. These risk factors, as investigated by several teams, [29-33] include age, sex (being
male), diabetes duration and type, insulin use, past history of diabetic foot ulcer (DFU) and
amputation, lower limb bypass procedures, biomechanical factors such as glycaemia level and
poor glycaemic control, dyslipidaemia, sensory and autonomic neuropathy (foot insensitivity
to the 5.07 monofilament), absence of reflex and limited joint motion, muscle weakness, callus
formation, Charcot deformity, hammer/claw toe deformity, abnormal Achilles tendon reflex,
greater body mass (≥20kg), arterial insufficiency, vascular disease, skin dryness and fissure
(caused by autonomic neuropathy), reduced skin oxygenation and foot perfusion (defined as
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ankle-brachial index ABI<0.9, toe systolic pressure <45 mmHg, 13mmHg orthostatic blood
pressure fall and 15mmHg higher dorsal foot transcutaneous PO2), diastolic hypertension,
impaired vision, as well as socio-environmental risk factors in some communities, such as
smoking habits, alcohol consumptions, lack of proper diabetes educations, low income, racial
distribution (African Americans, Hispanic Americans and Native Americans face a higher
risk), poor personal hygiene and self-care.
Smoking, hypertension, and hyperlipidemia are considered as risk factors due to their effects
on the increased occurrence of peripheral arterial occlusive disease in diabetics, which typically
involves the tibial and peroneal arteries, but leaves the dorsalis pedis artery unaffected. [14]
There are controversies on some other factor, as some studies could not find a relationship
between them and DFU occurrence. They include height, hallux blood pressure, and other foot
deformities. [34,35] Also, although some studies could not find a statistically significant
association between the length of diabetes and the risk of DFU, other studies mentioned it
could be predictive. [36]
Wounds that are penetrated to bone, wounds older than 30 days, recurrent wounds, and
presence of peripheral vascular disease increase the risk of wound infections. [37]
The majority (80%) of DFUs is the consequences of neuropathies due to decreasing pain
sensation and perception of pressure, to causing muscle imbalance that can lead to anatomic
deformities, and to impairing the microcirculation and the integrity of the skin. Therefore, risk
factors in neuropathy should also be considered as risk factors in DFU. They include unbal‐
anced age, sex (male gender), duration of diabetes, higher glycemia level, higher levels of LDL
and triglycerides, higher von Willebrand factor levels and urinary albumin excretion rate,
hypertension, depression and atherosclerosis (ischemia). [34,38,39]
12. Symptoms and prediction
Diabetic foot ulcers usually start with the following symptoms:
• Atrophic integument
• Any break in the skin resulted from abnormal wear and tear, injury, or infection
• Sores, ulcers, or blisters on the foot or lower leg
• Persistent pain, which can be a symptom of sprain, strain, bruise, overuse, improperly fitting
shoes, or underlying infection.
• Calluses and corns that may be a sign of chronic trauma to the foot
• A claudicating or difficulty walking that can be sign of joint problems, serious infection, or
improperly fitting shoes
• Discoloration in feet: black, blue, or red
• Cold feet
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• Absent pulses
• Swollen foot or ankle
• Odor
• Fever or chills in association with a wound that can be a sign of a limb-threatening or life-
threatening infection
• Redness, which can be a sign of infection, especially when surrounding a wound, or of
abnormal rubbing of shoes or socks.
• Swelling of the feet or legs, which can be a sign of underlying inflammation or infection,
improperly fitting shoes, or poor venous circulation.
• New or lasting numbness in the feet or legs, a sign of nerve damage from diabetes
• Signs of poor blood circulation, such as:
◦ Pain in the legs that increases with walking but improves with rest (claudication)
◦ Absence of pedal hair or pallor on elevation (coupled with other symptoms)
◦ Hard shiny skin on the legs
◦ Toenail fungus, athlete's foot, and ingrown toenails, which may lead to more serious
bacterial infections
• Drainage of pus from a wound is usually a sign of infection. Persistent bloody drainage is
also a sign of a potentially serious foot problem.
13. Classification of foot ulcers
Several schemes have been used to classify diabetic foot ulcers, but none of them has been
accepted universally. Following is a list of the most used classifications: [40]
Wagner-Meggitt, the most popular method that was described by Meggitt (1976) and Wagner
(1982), [41,42] has been used for decades to classify DFUs in six grades based on the wound’s
depths and extent of gangrene (table 2):
Grade 0 Intact skin (only foot symptoms like pain exist)
Grade 1 Superficial ulcer
Grade 2 Deep ulcer to tendon, bone or joint
Grade 3 Deep ulcer with abscess or osteomyelitis
Grade 4 Forefoot gangrene
Grade 5 Whole foot gangrene
Table 2. Wagner-Meggitt grades of diabetic foot ulcer classification.
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University of Texas classification, which has been developed by Armstrong and his colleagues,
is a more comprehensive scale and includes risk stratification and expresses tissue breakdown,
infection and gangrene separately (table 3). [42] The University of Texas scale showed a better
correlation with prognosis and risk of amputation: [14]
Grade 0 Pre-ulcerative site, or healed ulcer.
Grade 1
Ulcer through the epidermis +/- dermis, but not to tendon, capsule or bone
1A- without infection or ischaemia
1B- with infection but no ischaemia
1C- with ischaemia
1D- with ischaemia and infection
Grade 2
Ulcer to capsule or tendon
2A- without infection or ischaemia
2B- with infection but no ischaemia
2C- with ischaemia
2D- with ischaemia and infection
Grade 3
Ulcer to bone or joint
3A- without infection or ischaemia
3B- with infection but no ischaemia
3C- with ischaemia
3D- with ischaemia and infection
Table 3. University of Texas grades of diabetic foot ulcer classification
Although Texas classification describes the grade of wound in more details, it does not include
measures of neuropathy or ulcer area.
S(AD) SAD system builds upon the Wagner classification to include several additional
categories: size (area, depth), sepsis, arteriopathy and denervation. [43] Developed by an
English group, the S(AD) SAD classification is a validated system with grades 0 to 3, [44] as
shown in table 4:
Grade Size Sepsis Arteriopathy Denervation
Area Depth
0 Skin intact Skin intact None Pedal pulses present Pin pricks intact
1 < 1 cm2 Superficial (skin andsubcutaneous tissue) Surface
Pedal pulses reduced
or one missing
Pin pricks
reduced
2 1-3 cm2 Tendon, periosteum, jointcapsule Cellulitis
Absence of both pedal
pulses
Pin pricks
absent
3 > 3 cm2 Bone or joint space Osteomyelitis Gangrene Charcot
Table 4. S(AD) SAD classification for diabetic foot ulcer
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RYB Color Classification was developed for the nursing literature [45] and has obtained
considerable popularity.  The system relies  purely on a  color  scheme with no additional
considerations.  R/Red wounds are  those that  exhibit  pale  pink to  beefy red granulation
tissue and are deemed to be in the inflammatory or proliferative phase. Y/Yellow wounds
are marked by pale ivory, yellowish green or brown color,  slough of necrotic but moist
tissue,  and wound exudates.  B/Black wounds are marked by black,  brown or tan color,
and desiccated eschar. The RYB classification is an easy and widely accepted system in the
nursing literature and shows the continuum from acute to chronic wounds. Conversely, it
is  non-specific  with  no  consideration  of  depth  or  size,  and  no  consideration  of  the
contributing factor of neuropathy.
PEDIS classification was  proposed by the  International  Working Group on the  Diabetic
Foot  [46,47]  and  grades  the  wounds  on  the  basis  of  five  features:  perfusions  (arterial
supply), extent (area), depth, infection and sensation. There are levels of 1 to 4 for each of
these factors. The in-depth nature of this system is appropriate for the research communi‐
ty that desires this amount of detail. Every lesion is described (for example P2E1D2I1S2),
according to table 5:
Grade Perfusion (P) Extent/size(E) (cm2) Depth/tissue loss (D) Infection (I) Sensation (S)
1 no symptoms/signs of PAD
Superficial full-thickness
ulcer no symptoms/signs
No loss of
protective
sensation
2
symptoms or
signs of PAD, but
not CLI
Ulcer penetrating below
dermis to skin structures
Inflammation of skin
only
Loss of
protective
sensation
3 CLI
All subsequent layers of
foot, including bone/
joint
Extensive erythema
deeper than skin
4
Systemic inflammatory
response syndrome
(SIRS)
Table 5. Grades of PEDIS classification for diabetic foot ulcer
Determination of the level of infection in PEDIS classification system is based on the Severity
Classification guideline published by the Infectious Disease Society of America (IDSA), as
shown in table 6:
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Clinical Manifestation of Infection InfectionSeverity
PEDIS
Grade
Wound lacking purulence or any manifestations of inflammation. Uninfected 1
Presence of ≥ 2 manifestations of inflammation (purulence, or erythema, pain,
tenderness, warmth, or induration), but any cellulitis/erythema extends ≤ 2 cm around
the ulcer, and infection is limited to the skin or superficial subcutaneous tissues; no
other local complications or systemic illness.
Mild 2
Infection (as above) in a patient who is systemically well and metabolically stable, but
which has ≥ 1 of the following characteristics: cellulitis extending > 2 cm, lymphangitic
streaking, spread beneath the superficial fascia, deep-tissue abscess, gangrene, and
involvement of muscle, tendon, joint, or bone.
Moderate 3
Infection in a patient with systemic toxicity or metabolic instability (e.g., fever, chills,
tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe
hyperglycemia, or azotemia).
Severe 4
Table 6. Severity classification guideline according to IDSA
DEPA Scoring System, is the newest DFU classification system, in which D stands for depth
of the ulcer, E for extent of bacterial colonization, P for phase of ulcer, and A for associated
etiology (table 7). [48] Ascending scores, from 1 to 3, are assigned for increasing levels of
intensity in each category (see the table below). For instance, an ulcer involving soft tissue
receives a 2. Contamination of this ulcer receives a 1. The ulcer is in the inflammatory phase,
generating a 2 score, and has an underlying bony deformity, generating another 2 score.
Accordingly, this ulcer has a total score of 7. Ulcers with a total score of 6 or less are considered
“low grade” ulcers. Recommended treatment measures include oral antibiotics (if infected),
blood sugar control (type not specified) and debridement. Those with a total score of 7 to 9 are
deemed “moderate grade” wounds that one would treat with parenteral antibiotics, insulin,
debridement, healing promoting agents and pressure relieving methods. The “high grade”
lesions, those with a total score between 10 and 12, require a conservative trial including
parenteral antibiotics, insulin, debridement, healing promoting agents and vascular recon‐
struction. The authors of the DEPA classification system offered acute ischemia patients a
below-knee amputation; however, other practitioners may offer revascularization or other
interventions. The scores of 11 to 12 are prognostic for amputation and if these are heel ulcers,
they were even more likely to lead to amputation. Scores of 10 or greater predict difficulty with
healing, while scores of 6 or less indicate probable healing.
Gangrene Management - New Advancements and Current Trends60
DEPA Score
Score
1 2 3
Depth of the ulcer Skin Soft tissue Bone
Extent of bacterial colonization Contamination Infection Necrotizing infectiona
Phase of ulcer Granulatingb Inflammatoryc Nonhealingd
Associated etiology Neuropathy Bone deformity Ischemiae
a Infected ulcer with surrounding cellulitis or fasciitis.
b Evidence of granulation tissue formation.
c Hyperemic ulcer with no granulation tissue <2 weeks’ duration.
d Nongranulating ulcer >2 weeks’ duration.
e Clinical signs and symptoms of chronic lower-limb ischemia.
Table 7. Scores and definitions of DEPA scoring system
14. Vascular impaired in foot ulcers
Vascular impairment is one of the most important causes of DFU, and in addition to hyper‐
glycemia, is the main impediment in healing the ulcers. Smoking cessation, diet improvement
and controlling total and LDL cholesterol, antiplatelet drug treatment, and maintaining an
optimum blood pressure will help reducing the impact of vascular impairment on ulcer
healing. Vascular impairment in foot ulcers has been discussed in more details in 7.
15. Angiogenesis in foot ulcer
When a tissue is injured, blood from the broken capillaries streams into the wound. This blood
carries platelets and fibrinogen. Fibrinogen is activated in response to the exposed epithelium
to form a fibrin mesh that traps platelets. Platelets also adhere to the ruptured blood vessels,
preventing further blood loss. Moreover, platelets come into contact with damaged ECM
components; they release clotting factors, leading to the formation of a blood clot within the
wound site. The activated platelets in the wound release chemical stimuli such as platelet-
derived growth factor (PDGF), transforming growth factor-β (TGF-β), and vascular endothe‐
lial growth factor (VEGF). [49,50] Fibroblasts stimulated by these chemoattractants produce
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collagen, which is a major component of the ECM, a scaffold onto which the endothelial cells
can migrate to create and extend the vascular network. Fibroblasts also secrete PDGF and TGF-
β, as well as VEGF. This cocktail of growth factors stimulates the endothelial cells of vessels
in the nearby healthy tissue to release proteases such as MMPs. [51] MMPs digest the basement
membrane, allowing endothelial cells to escape the confines of their parent vessels. [52] VEGF,
EGF, bFGF, and TGF-β stimulate the systematic rearrangement of endothelial cells from blood
vessels. The cells proliferate, elongate, and align to form a capillary sprout, extending away
from the original vessel. [49] This is the beginning of the angiogenesis process. Then, polarized
endothelial cells are positioned with a luminal and an abluminal surface forming tubular
structures, which act as a multipurpose barrier between the flowing blood and the extrava‐
scular tissue. Periendothelial cells, such as pericytes, fibroblasts, and smooth muscle cells,
reinforce these tubular endothelial networks. This process is oxygen dependent. Oxygen is
required for collagen deposition. Hypoxia causes the hypoxia-inducible factor (HIF) to up-
regulate the production of VEGF.
Sprout extension is facilitated by endothelial cell proliferation and further migration toward
the chemical attractant.
Vasculogenesis, the formation of blood vessels from the differentiation of progenitor cells, also
plays a part in the formation of new blood vessels during this stage of wound healing. [53]
Progenitor cells differentiate into early endothelial progenitor cells in the bone marrow and
further differentiate into late endothelial progenitor cells in the vasculature system before
arriving at the site of vessel formation. [52]
The joining of two capillary sprouts within a healing wound forms a loop through which blood
can flow and new sprouts develop from this vessel thus propagating angiogenesis. [54] This
capillary extension allows oxygen and other critical nutrients to be transported further into
the injured region. This, in turn, allows the macrophage and fibroblast fronts to migrate further
into the wound, and thus the healing unit progresses into the injured tissue. [54] When the
unit has completely swept through the wound site, blood vessels are networked over the entire
space and oxygen levels are returned to normal. Oxygen binds to HIF and leads to a decreased
synthesis of VEGF. This ends the angiogenesis process. [49]
Usually diabetes causes excessive and deficient angiogenesis (table 8). Therapeutic factors that
can regulate angiogenesis in the diabetic foot conditions are considered as successful treat‐
ments for DFU.
16. Diagnostic tests and prediction
A task force of the Foot Care Interest Group of the American Diabetes Association (ADA)
released a report in 2008 that specifies recommended components of foot examinations for
patients with diabetes (table 9). [55]
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Risk
Category Definition Treatment Recommendation Suggested Follow-up
0 No LOPS, no PAD, nodeformity
Consider patient education on foot care,
including information on appropriate footwear.
Annually (by generalist
and/or specialist)
1 LOPS±deformity
Consider prescriptive or accommodative
footwear.
Consider prophylactic surgery if deformity is not
able to be safely accommodated in shoes.
Continue patient education.
Every 3-6 months (by
generalist or specialist)
2 PAD±LOPS
Consider the use of accommodative footwear.
Consider a vascular consultation for combined
follow-up.
Every 2-3 months (by
specialist)
3 History of ulcer oramputation
Consider patient education on foot care.
Consider vascular consultation for combined
follow-up if PAD present.
Every 1-2 months (by
specialist)
LOPS, loss of protective sensation; PAD, peripheral arterial disease. Adapted from [55]
Table 9. Risk classification system of the Task Force of the Foot Care Interest Group of the ADA
Defective angiogenesis Excessive angiogenesis
Phenotype Causes Phenotype Causes
Reduced
angiogenesis and
collateral formation
Reduced VEGF, FGF, EPC circulation,
cytokines, ECM/BM degradation;
increased AGEs and MMP
Retinal capillary
occlusion
Elevated intraocular
pressure
Vascular occlusion,
inflammation
Increased free fatty acids, polyol
pathway, cytokines, ICAM, VCAM
Increased vascular
permeability Increased VEGF
Reduced wound
healing; transplant
failure
Reduced VEGF and growth factors;
sorbitol-inositol imbalance; increased
ACE, Ang-II and tissue factor mRNA
Capillary sprouting
Increased VEGF, FGF,
PDGF; cytokines (TGF-β);
integrins
Embryonic
vasculopathy
(anomalous
vasculogenesis and
angiogenesis)
Reduced VEGF, IL-1, TGF-β Vascular remodeling
Increased laminin,
fibronectin, collagen IV,
ECM components,
lipidosis
Table 8. Comparison of aberrant angiogenesis under diabetes.
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Foot deformity is an important diagnostic sign for future foot ulcer. In addition to Charcot
arthropathy, hyperextension of the metatarsal-phalangeal joint with interphalangeal or distal
phalangeal joint flexion leads to hammer toe and claw toe deformities, respectively. The
deformities may lead to ulceration by continuous improper contact with the footwear.
In examining for vascular abnormalities of the foot, the dorsalis pedis and posterior tibial
pulses should be palpated and characterized as present or absent. Claudication, loss of hair,
and the presence of pale, thin, shiny, or cool skin are physical findings suggestive of potential
ischemia. [56] If vascular disease is a concern, measuring the ankle brachial index (ABI) can
be used in the outpatient setting for determining the extent of vascular disease and need for
referral to a vascular specialist. The ABI is obtained by measuring the systolic blood pressures
in the ankles (dorsalis pedis and posterior tibial arteries) and arms (brachial artery) using a
handheld Doppler and then calculating a ratio. However, in patients with calcified, poorly
compressible vessels or aortoiliac stenosis, the results of the ABI can be complicated. [57]
The loss of pressure sensation in the foot has to be identified using a 10-guage monofilament
as a significant predictive factor for the likelihood of ulceration. [57]
High vibration perception thresholds (VPTs) using a biothesiometer or a tuning fork, high
plantar pressure and 10-gauge monofilaments are used as reliable methods to identify those
at risk of future ulceration. [36]
17. Foot amputation
Despite all efforts to treat ischemic and neuropathic ulcers, sometimes the lower-extremity is
non-viable and amputation is inevitable. Non-traumatic amputations are high in poorer
countries and in uneducated people in wealthy countries. Amputees suffer from direct surgical
morbidity and mortality, inadequate and delayed rehabilitation. Also, amputees attract great
amount of care from a multidisciplinary team and put additional pressure on countries’ health
systems and disability insurances.
The indications for amputation in patients with diabetes are often multiple, mostly a non-
healing ulcer, or frequent gangrene and infection occurring simultaneously. [58] Whether
primary minor amputation is beneficial in comparison with primary major amputation (below
knee) is still controversial. Digital toe amputation eventually leads to limb loss, while a major
amputation lowers the risk of re-amputation. [59] Re-amputation widely rates from 21% to
60%, and is greatest in the first 6 to 12 months after the first amputation. [60,61] Once hallux
has gone under amputation, changes in mechanical force and pressure on the foot may increase
the likelihood of developing further lesions, most probably within 6 months. [62] Studies by
Byrne et al. 1992 and Yeager et al. 1998 showed that revascularization may not prevent re-
amputation as patients undergoing revascularization procedures are likely to have severe
ischaemic disease. [63,64]
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18. Treatments
Any diabetic patient with a skin break below the knee that has not healed with appropri‐
ate care in 2 weeks should be referred urgently to a suitable specialist for an assessment.
Assessment of the cause of an ulcer helps clinicians in determining the most appropriate
treatment.  The  assessment  includes  testing  for  sensation,  palpating  for  foot  pulses,
measuring the ankle-brachial pressure index (ABPI) and toe pressures, and often undertak‐
ing  color-flow duplex  ultrasonography.  Patients  with  lower-limb tissue  loss  from ische‐
mia should be assessed by a vascular surgeon. Magnetic resonance angiography (MRA) or
conventional  intra-arterial  digital  subtraction angiography could be needed to help plan
the reconstruction. [65-68]
DFU can be successfully treated by a multidisciplinary team consists of diabetologist, shoe‐
maker, orthopedist, psychologist, vascular and general surgeons, podologists, radiologists,
educators, nurses and rehabilitation team. [35]
Surgeons (general, vascular, orthopaedic, plastic, podiatric) generally become involved in
treating severe tissue infection, especially when gangrene or underlying osteomyelitis remain
despite antibiotic treatment. [69] The main purpose of surgery is to remove infected and
necrotic soft and bony tissue back to a healthy base that will support granulation tissue and
allow healing by secondary intention.
Many diabetic patients with underlying ischemia will need revascularization to provide an
adequate arterial blood supply in order to achieve a better healing and resolve underly‐
ing infection. Up to a 90% 10-year limb-salvage rate has been demonstrated with surgical
bypass procedures of the lower extremity. [70] A standard treatment for ischemic ulcera‐
tion  is  still  femorodistal  bypass  with  an  autogenous  tissue  (usually  saphenous  vein),
although this treatment is not readily available for all patients. However, it seems reason‐
able to attempt healing of ischemic and neuroischemic ulcers with drugs before consider‐
ing revascularization.
Conventional treatments for diabetic peripheral neuropathy include tricyclic compounds,
serotonin-norepinephrine reuptake inhibitors (e.g. duloxtine), anticonvulsants (e.g. pregaba‐
lin), opiates, membrane stabilizers, the antioxidant alpha lipoic acid and others. [33]
The selection of wound dressings is also an important component of diabetic wound care
management. Advanced wound dressing products can help alter the wound environment to
optimize healing conditions. Characteristics of a successful wound dressing will be discussed
later.
If not managed properly, diabetic foot ulcers are at high risk for infection. Open wounds can
be contaminated or infected with microorganisms and even virulent pathogens. The generally
accepted clinical definition of infection is the presence of purulent secretions or at least two
signs or symptoms of inflammation (erythema, warmth, tenderness, pain, and induration).
While ischemia or neuropathy signs such as friable tissue, wound undermining, and foul odor
imply infection. [71] Most diabetic foot infections do not produce systemic signs, such as fever
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or leukocytosis, but when they are present, they typically suggest that any accompanying
infection is severe.
To assess the infection, clinicians should obtain material for a wound culture. Tissue specimens
are strongly preferred to wound swabs, because they provide more sensitive and specific
results. Tissue can be obtained by scraping of the base of the ulcer with a scalpel or dermal
curette (curettage) or by wound biopsy. Aseptically obtained aspirates of pus (purulent
secretions) or tissue fluid can also provide good specimens for culture. The specimen should
be processed for both aerobic and anaerobic cultures and a gram-stained smear, if possible.
Blood obtained for a complete blood count (and leucocyte differential), basic serum chemistry
panels, and inflammatory markers (erythrocyte sedimentation rate [ESR] or C-reactive
protein) can help define the severity of the infection. [72]
Usually, plain radiographs of the foot will help to identify foreign bodies, gas in the tissues,
or evidence of osteomyelitis. More sophisticated imaging tests (the best of which being MRI)
might be needed to better define the presence or absence of bone or deep soft-tissue infection.
Infection of bone underlying a foot ulcer is an especially difficult diagnostic and therapeutic
problem. Osteomyelitis is probably present if the bone is visible or palpable by probing. Bone
infection must usually be present for at least 2 weeks before it can be regarded as the cause of
abnormalities seen on plain radiographs. Most nuclear medicine tests (e.g., technetium bone
scans or labeled leucocyte scans) are more sensitive than plain radiography, but are relatively
non-specific and less accurate than MRI. The gold standard test for osteomyelitis is a bone
biopsy sample processed for culture and histology. [73]
All available data are required to decide whether infections are safe to treat on an outpatient
basis, or whether hospital care is needed for medical, diagnostic, surgical, or psychosocial
reasons. [30]
Antibiotics are selected largely based on the probable causative organisms, taking into account
any known local antibiotic resistance patterns. Patients with severe infections need parenteral
treatment, at least initially; oral therapy is often adequate for those with mild or moderate
infections. [74]
Topical antimicrobials are often effective for mildly infected ulcers, however, some topical
antiseptics can impair wound healing, but dressings containing silver or iodine seem to be
safe, and possibly useful (see later). [75]
The aim of antimicrobial therapy is to cure the infection, not to heal the wound; extended
treatment increases the risk of drug-related toxic effects and development of antibiotic
resistance. Antibiotic treatment without off-loading a plantar wound (i.e., the relieving of a
mechanical load) is unlikely to result in ulcer healing (see later).
Bone infection is best treated by surgical resection of all  infected and necrotic bone, but
retrospective studies suggest that long-term treatment (at least for 4–6 weeks) with drugs
that  penetrate  well  into  bone  (e.g.,  fluoroquinolones)  can  often  produce  a  remission  of
infection. [73]
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19. Treatment-based classification system for the diabetic foot
Recently developed treatments for diabetic foot ulcers include the use of bone marrow-derived
stem cells, [76] use of human or bioengineered skin equivalents, [77,78] growth-factor therapy
(such as using PDGF or G-CSF) [79,80] and negative pressure wound therapy (NPWT) [81].
Hyperbaric oxygen treatment (HBOT) seems to reduce the risk of major amputation, but not
the time to ulcer healing or the rate of minor amputation. [82,83] Routine debridement of
devitalized tissue at follow-up visits is widely recommended. [84] Maggot (larval) biotherapy
seems to be effective for debridement [85] and acceleration of healing, [86,87] and perhaps also
in reducing antibiotic use and risk of amputation. [88] A recently developed natural-based
medicine, ANGIPARSTM, has shown excellent effects on wound closure and shortening the
wound healing period in both diabetic foot ulcers [89-93] and pressure ulcers, [94,95] via strong
angiogenesis, anti-oxidant, [96] anti-coagulant and properties.
Negative Pressure Wound Therapy (NPWT) is a sealed wound-care system and is particularly
indicated for a large chronic persistent wounds and acute complicated wounds. The system
consists of an electronically controlled pump and a foam dressing that drains the wound. [97]
An adjustable negative pressure is applied via an airtight adhesive film that covers the wound.
NPWT drains wound exudates and is thought to promote blood circulation and healing. [98]
NPWT benefits include increased local blood flow, [99] rapid wound granulation, increased
number of active fibroblasts and macrophages, [99] epithelial isolation, migration and
contraction, [94,95] reduction of dressing changes, [100] reduced infection risk, [101] reduced
treatment costs, [59] control of exudates that contain harmful fluid and by-products of tissue
damage, [99,102] concurrent rehabilitation, [103] and better patient tolerance. [104] However,
it is impossible to conclude from the studies that NPWT performs absolutely or relatively better
than the control treatments in terms of wound healing. [105] Only one study showed a
statistically significant difference in wound healing in the test group compared to the control.
Although a few studies showed some NPWT effect in shortening the wound closure time, its
total efficacy cannot be fully concluded because the studies were not properly designed in
terms of methods of measurement, blinding and follow-ups. [106] There was high potential
for bias and diagnostic heterogeneity in the studies. To approve if NPWT has a positive effect
on wound healing, further research clinical trials of good methodological quality are required.
Moreover, the FDA recently issued a report on six deaths and 77 other complications that were
reported within a two-year period in connection with NPWT. All the deaths were caused by
acute hemorrhages, and known contraindications for NPWT (e.g. a large blood vessel exposed)
had clearly been overlooked. Many of the deaths occurred in outpatient care or care homes,
which highlights the need to monitor therapy. [59,107]
Hyperbaric Oxygen Treatment (HBOT), which is used for Wagner Grade 3 diabetic wounds
that have failed to resolve after a 30-day course of standard treatment, is the delivery of pure
oxygen to patients at higher than normal atmospheric pressures to compensate shortage of
blood oxygen due to vascular impairment. [83] The usual pressure for treating DFU is 1.4 to 3
atmospheres absolute pressure (ATA) - with an optimum of 2 ATA - for a compression time
of 60 to 120 minutes - with an optimum of 90 minutes - during a course of multiple treatments.
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[97,108,109] This high pressure results in an increase in the concentration of oxygen in the
blood and an increase in the diffusion capacity to the tissues, which, in turn, stimulates
neovascularization and fibroblast replication and increases phagocytosis and leukocyte-
mediated killing of bacterial pathogens in the wound. [109] A long benefits list of increasing
the tissue oxygen is made through several studies [50]: modulation of the production of nitric
oxide, promotion of cellular proliferation, stimulation of capillary budding, alteration of
ischemic effect, modification of the effect of growth factors and cytokines, acceleration of
collagen deposition, reduction of edema, modulation of the immune system response,
accelerated microbial oxidative killing, and enhancement of oxygen radical scavengers,
thereby reducing ischemia reperfusion injury.
There is enough good evidence that HBOT decreases risk of amputation in patients with
complicated or infected DFU. [110,111] Many studies have shown that HBOT results in partial
or complete wound healing. Some studies also showed that HBOT in combination with surgery
and antibiotics can be used to treat refractory osteomyelitis. HBOT is reasonably safe when
administered by experienced practitioners after careful patient screening and selection. [112]
Wound dressing, widely used to cure the infected wounds, is the most important component
of a successful wound care. There are a number of available dressing types to consider.
Although there is a shortage of published trials to support the use of one type of dressing
compared to another, [113] the characteristics of specific dressing types can prove beneficial
depending on the characteristics of the individual wound. An ideal dressing should contribute
to a moist wound environment, absorb excessive exudates, and not increase the risk for
infections. [114] Dressing changes and wound inspection should occur on a daily basis. [113]
Saline-soaked gauze dressings, for example, are inexpensive, well tolerated, and contribute to
an atraumatic, moist wound environment. Foam and alginate dressings are highly absorbent
and can aid in decreasing the risk for maceration in wounds with heavy exudates.
The process of autolysis is important in wound care. If an occlusive dressing is provided as a
barrier to the outside environment, the body’s own phagocytic processes will provide
debridement of wounds. These products range from occlusive films such as Tegaderm, which
are permeable to air and water vapor, but impermeable to fluid and microorganisms to
hydrocolloids such as DuoDerm, which are also occlusive but provide absorption of exudates
in addition to maintaining a moist environment for autolysis. For heavily exudative wounds,
there are a range of absorptive products, including various hydrophilic foam dressings,
hydrogels, hydrofibers, and alginates, which can absorb up to 20 times their weight. [115]
Silver dressings have been used for decades with little significant toxicity to cure infected
wounds. Silver has a very broad spectrum of microbial coverage, including yeast, fungi, mold,
and even antibiotic-resistant organisms, when used at appropriate concentrations. Silver ion
binds to negatively charged particles such as proteins, DNA, RNA and chloride ions. [116,117]
Introduced in 1968, silver sulfadiazine is known to release active silver ion gradually for a
longer time. [118] Nanocrystalline silver dressing developed since 1990s to fix the shortcom‐
ings of this type of dressing. It contains two layers of high-density polyethylene net sand‐
wiching a layer of rayon/polyester gauze. The outer layer is coated with a nanocrystalline (<20
nm), uncharged form of silver, and the inner layer helps maintain a moist environment for
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wound healing. [116] This sandwich provides a sustained release of silver into the wound due
to the low affinity of Ag0 to the negatively-charged particles in the wound. Other advantage
of nanocrystalline silver dressing is less frequency of dressing changes compared the standard
silver dressings, which must be changed up to 12 times a day. This brings less disruption to
the wound healing bed.
Growth factors play the most important role in orchestrating the cells in wound bed along the
process of wound healing. When a wound occurs, platelets and fibroblasts recruited to the
wound bed, start secreting growth factors, such as PDGF, VEGF, EGF, G-CSF (GM-CSF), and
TGF-β. G-CSF or GM-CSF has been found to enhance the activity of neutrophils, macrophages,
keratinocytes, and fibroblasts, and increase VEGF production in diabetic patients. [119,120] A
meta-analysis study revealed that, although the use of G-CSF did not significantly accelerate
the resolution of infection in diabetic wounds, there was a decreased likelihood of amputation
and the need for other surgical therapies in treated wounds. [121]
In a study by Steed et al., patients who were treated with recombinant human platelet-derived
growth factor (rhPDGF) showed statistically significant higher percentage of wound healing
(48% vs. 25% in control group), as well as greater reduction in wound size. Now, known as
becaplermin or Regranex, rhPDGF is used in treatment regimens for DFU. [122,123]
Stem cell therapy has emerged as a promising treatment modality aiming to address the
underlying pathophysiology of DFU. Stem cells secrete chemokines and growth factors
(especially EGF, VEGF and fibronectin), which promote angiogenesis and ECM remodeling
to mobilize wound healing. Stem cells that have been studied for wound healing can be
classified in two groups of allogenic and autologous, based on where their origins are. Placental
or amnion-derived mesenchymal stem cells and embryonic stem cells are categorized as
allogenic stem cells. On the other hand, bone marrow-derived endothelial progenitor cells,
bone marrow-derived mesenchymal stem cells, hematopoietic stem cells, and mesenchymal
stem cells derived from adipose tissue are the autologous stem cells. [124] Placenta-derived
MSCs are shown to be more effective in chronic wound healing. [125,126] Also, isolated ESC-
derived EPCs were shown to improve re-epithelialization when injected subcutaneously into
or applied topically on to the wound. [127] In another study, bone marrow-derived stem cells
were applied on to chronic wounds that were not healed for more than a year. The treated
wounds showed signs of closures within 2-4 weeks post-treatment, where there was a direct
correlation between the number of cells applied and the percent decrease in wound size. [128]
Another study also showed 81% limb salvage when bone marrow-derived stem cells were
injected to the wounds that were otherwise candidates for amputations. [129] Hematopoietic
stems cells (HSCs), harvested from either bone marrow or peripheral blood, are shown to
enhance wounds healing in both the inflammatory and proliferative phases of DFU. [130]
Despite promising results, the majority of these studies are conducted in animals and the few
human studies are not providing enough documents to include the stem cell therapies in fixed
treatments protocols of foot ulcers. More studies are required to demonstrate the safety,
efficacy and improved healing rates. The main obstacle stem cell therapy strategies are facing
is a proper system of delivering cells to the precise location within the wound. [124] One other
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major reason for limited adoption of stem cells or their products is the cost of obtaining and
preparing the cells. [74]
Bioengineered skin and skin grafts have also been investigated for wound healing. Tissue-
engineered skin substitutes are usually categorized in allogenic cell-containing and autologous
cell-containing matrices (both carry living keratinocytes or fibroblasts), as well as acellular
matrices. They all release growth factors to stimulate wound healing. [131,132] Some degrees
of healing have been demonstrated through some studies, [133-138] however, because the
results were susceptible to bias due to the poor methodology, more studies are required to
confirm those results. [139]
ANGIPARSTM, an herbal-origin drug, has shown promising results during phase II and III, and
post-marketing phase IV studies. [90-93,140] The main ingredient of this medicine is an herb,
called Melilotus officinalis (yellow sweet clover). Melilotus extracts are shown to have anti-
inflammation, anti-spasmodic, aromatic, carminative, diuretic, emollient, mildly expectorant,
mildly sedative and vulnerary effects. Therefore, ANGIPARSTM was expected and proved to
possess angiogenesis, anti-oxidative and anti-inflammatory properties, and to be able to improve
the local blood circulation and provide trace elements effective in the wound healing. Exces‐
sive studies had shown that it was effective in treating DFU and decubitus ulcer, and in preventing
from amputation. In those studies, an obvious wound healing was observed after a 4-week
therapy period. The Producer suggests the following indications and clinical uses: [141]
• Adult patients with diabetes type 1 and 2 suffering from single and multiple foot ulcer(s)
in Wagner’s grade 1 and 2, and infection-controlled grade 3.
• Patients with foot ulcers that are caused due to peripheral neuropathy or other neuropathies,
foot deformities, traumas, using unsuitable shoes, history of foot ulcer or amputation, joint
movement limitation, uncontrolled hyperglycemia, prolonged diabetes, etc.
A widely-collective document registration on case reports is required to confirm ANGI‐
PARSTM as a potent drug in DFU treatment. [74]
20. Foot care and management of foot ulcer
One of the easiest, least expensive and most effective ways for preventing foot complications
could be careful inspection of the diabetic foot on a regular basis. [14]
Initial management consists of cleansing of the wound, debriding of any necrotic or gangre‐
nous material, and the probing (preferably with a blunt sterile metal instrument) for foreign
bodies or exposed bone.
There is no doubt that one of the most important parts of DFU treatments or prevention plans
should be off-loading, meaning pressure relief on ulcer. High plantar pressure is usually
caused by bony deformity or displacement of soft tissues, and may lead to ulceration and
failure to heal. Ulcers can also be caused by contact between the dorsal surface of deformed
toes and footwear that does not provide adequate toe room.
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A successful off-loading through a total contact cast can decrease the pressure from 1000 kPa
to less than 100 kPa. [142] Total casts should be properly made and changed at least weekly.
It has been shown that patients bearing ulcer are not usually complaint with a removable off-
loading device. [143] Various ambulatory braces, splints, modified shoes, and sandals can off-
load the plantar surface or immobilize the foot and ankle or both. A modified half-shoe can
help off-load pressure from half of the foot. Felted-foam, soft polymeric insoles and orthoses
with load-isolation regions are also used to smoothen the inner layers of shoes. [144] For
interdigital lesions, the close or overlapping toes must be separated. Ulcers on the plantar
aspect of the heel take longer to heal than those on the forefoot in total contact casts and could
benefit from special shoes without a rear-foot platform.
DFU patients are encouraged to reduce their activity levels temporarily. Patients are typically
less active in total contact casts than in healing shoes, presumably because of the bulk and
weight of the irremovable device. Increased activity, with the consequent high cumulative
load, can delay or prevent ulcer healing. [145]
21. Prevention of diabetic ulcer formation
Lifetime prevalence of DFU development is estimated 25% [29,32]. Recurrence rate is also
estimated to range from 28% at 12 months to 100% at 40 months. [146] At least 40% of ampu‐
tations in diabetic patients can be prevented with a team approach to wound care.
Early detection of potential risk factors for ulceration can decrease the frequency of wound
development. Diabetic patients should be educated regarding the importance of maintaining
good glycemic control, wearing appropriate footwear, avoiding trauma, and performing
frequent self-examination. They are also recommended to have their feet professionally
examined at least annually (see table 9, according to the Foot Care Interest Group of the ADA)
[55] to determine predisposing conditions to ulceration. In both self- and professionally-
examining the foot, visual inspection of the bare foot should be performed in a well-lit room.
The examination should include an assessment of the shoes; inappropriate footwear can be a
contributing factor to the development of foot ulceration. In the visual inspection of the foot,
the evaluator should check between the toes for the presence of ulceration or signs of infection.
The presence of callus or nail abnormalities should be noted. Additionally, a temperature
difference between feet is suggestive of vascular disease.
The foot should also be examined for deformities. The Charcot arthropathy is a commonly
mentioned deformity in some affected diabetic patients.
Regardless ulcer treatment method, patients should slowly change to full activity and weight-
bearing, using appropriate custom-made therapeutic footwear, while hyperglycemia, and
neuron and vascular conditions are under a careful watch. Moreover, a proper patient and
care-giver education, and regular foot care are of extreme importance in preventing DFU
recurrence.
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